Translocation (X; 20)(q13;q13.3): a nonrandom abnormality in four patients with myeloid disorders: case 1

Kavita S. Reddy, Kathy E Richkind
Genzyme Genetics, Orange, CA, USA (KSR); Genzyme Genetics, Santa Fe, NM, USA (KER)

Published in Atlas Database: January 2005
Online updated version: http://AtlasGeneticsOncology.org/Reports/0X20ReddyID100009.html
DOI: 10.4267/2042/38171

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence.
© 2005 Atlas of Genetics and Cytogenetics in Oncology and Haematology

Clinics
Age and sex
57 years old female patient.

Previous history
No preleukemia. Previous malignancy: Breast infiltrating ductal carcinoma treated with radiation and tamoxifen.

Organomegaly
No hepatomegaly, no splenomegaly, no enlarged lymph nodes, no central nervous system involvement.

Blood
WBC: 3.8X 10^9/l
HB: 11.4g/dl
Platelets: 160X 10^9/l

Cyto-Pathology
Classification
Diagnosis
Myelodysplastic syndrome (MDS): refractory anaemia.

Survival
Treatment
Maintenance therapy for MDS patient declined bone marrow transplantation (BMT).
Relapse: no
Status: Alive
Survival: 42 months

Karyotype
Sample: BM
Culture time: 24/48h unstimulated cultures.
Banding: G-banding.
Results: 46,X,t(X;20)(q13;q13.3)[5]/46,XX[15].

Fig. 1. Partial karyotypes of the translocation t(X;20)(q13;q13.3) for cases 1-4 (top to bottom). Arrows indicate the derivatives 20 and X.
References


This article should be referenced as such: